Announcement PDF ABN 16 165 160 841 ASX RELEASE 19 December 2024 Results of Extraordinary General Meeting Amplia Therapeutics Limited (ASX: ATX) (“Amplia” or the “Company”) is pleased to confirm that each of the resolutions put to its Extraordinary General Meeting held earlier today were carried. Details of the results of the meeting are attached. This ASX announcement is authorised for release by the Company Secretary. - End Investor Contact: Dr Chris Burns Chief Executive Officer chris@ampliatx.com Media Contact: H^CK Director, Haley Chartres haley@hck.digital +61 423 139 163 About Amplia Therapeutics Limited Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on Twitter (@ampliatx), Threads (@ampliatx) and LinkedIn. Level 17, 350 Queen Street, Melbourne VIC 3000 Email info@ampliatx.com www.ampliatx.com AMPLIA THERAPEUTICS LIMITED Extraordinary General Meeting Thursday, 19 December 2024 Results of Meeting The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2. Resolution details Resolution Resolution Type 1 Ratification of Placement Shares Ordinary 2 Issue of Attaching Options under the Placement Ordinary 3 Issue of Lead Manager Options Ordinary 4 Issue of Sub-Underwriter Options Ordinary 5 Issue PLC Shares and Opt to Dr Warwick Tong Ordinary 6 Issue PLC Shares and Opt to Dr Christopher Burns Ordinary 7 Issue PLC Shares and Opt to Dr Robert Peach Ordinary 8 Issue PLC Shares and Opt to Ms Jane Bell Ordinary Instructions given to validly appointed proxies Number of votes cast on the poll Resolution (as at proxy close) Proxy's Against Discretion 830,879 3,072,494 (where applicable) Result Carried / Not Carried For 125,751,824 96.99% 0.64% 2.37% 125,521,809 1,043,994 3,089,394 96.81% 0.81% 2.38% 152,875,378 2,499,494 3,072,869 96.48% 1.58% 1.94% 150,874,436 2,527,914 3,322,494 96.27% 1.61% 2.12% 151,727,535 672,900 3,072,494 97.59% 0.43% 1.98% 150,907,487 616,900 3,187,998 97.54% 0.40% 2.06% 149,687,245 1,337,404 3,072,494 97.14% 0.87% 1.99% 151,243,614 1,308,984 3,072,494 97.18% 0.84% 1.97% Abstain For Against Abstain* 26,441,848 128,824,318 830,879 26,441,848 99.36% 0.64% 128,611,203 1,043,994 99.19% 0.81% 155,948,247 2,499,494 98.42% 1.58% 154,196,930 2,527,914 98.39% 1.61% 154,800,029 672,900 99.57% 0.43% 154,095,485 616,900 99.60% 0.40% 152,759,739 1,337,404 99.13% 0.87% 154,316,108 1,308,984 99.16% 0.84% 26,441,848 108,420 171,150 3,083,232 3,843,776 4,459,018 95,405 26,441,848 108,420 171,150 3,083,232 3,843,776 4,459,018 95,405 Carried Carried Carried Carried Carried Carried Carried Carried * Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll. 1/1